Pa­tient dies in Pfiz­er’s Phase 2 Duchenne mus­cu­lar dy­s­tro­phy tri­al

A Duchenne mus­cu­lar dy­s­tro­phy pa­tient died of car­diac ar­rest on Fri­day in a Phase 2 tri­al of Pfiz­er’s gene ther­a­py, the phar­ma com­pa­ny con­firmed.

The pa­tient re­ceived for­dadis­tro­gene mova­parvovec in ear­ly 2023 as part of Pfiz­er’s DAY­LIGHT study en­rolling pa­tients 2 and 3 years old. As a re­sult of the boy’s death, Pfiz­er is paus­ing dos­ing in the crossover por­tion of its Phase 3 CIFFREO study in pa­tients 4 to 7 years old.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER